AUPH
Aurinia Pharmaceuticals Inc. NASDAQ Listed Sep 3, 2014$17.53
After hrs
$17.70
+0.97%
Mkt Cap $2.3B
52w Low $7.29
92.2% of range
52w High $18.40
50d MA $15.78
200d MA $14.58
P/E (TTM)
7.7x
EV/EBITDA
12.0x
P/B
4.0x
Debt/Equity
0.1x
ROE
36.3%
P/FCF
18.0x
RSI (14)
68.50
ATR (14)
$0.52
Beta
1.52
50d MA
$15.78
200d MA
$14.58
Avg Volume
1.3M
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
4464 Markham Street · Edmonton, BC V8Z 7X8 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 0.21 | 0.26 | +23.8% | 13.97 | +0.1% | +1.4% | +0.3% | -0.4% | +6.3% | -2.0% | — |
| Nov 4, 2025 | AMC | 0.16 | 0.23 | +43.8% | 14.27 | -3.4% | +1.3% | -3.5% | +4.7% | +1.9% | +5.3% | — |
| Jul 31, 2025 | AMC | 0.17 | 0.16 | -5.9% | 9.24 | +1.3% | +13.5% | +9.2% | +2.2% | -0.8% | -1.6% | — |
| May 12, 2025 | AMC | 0.08 | 0.16 | +100.0% | 8.12 | +0.7% | -3.7% | +0.4% | +3.8% | +0.5% | -1.5% | — |
| Feb 27, 2025 | AMC | 0.03 | 0.09 | +200.0% | 7.55 | -1.1% | +5.3% | +0.4% | +1.3% | +7.3% | -5.5% | — |
| Nov 7, 2024 | AMC | 0.01 | 0.10 | +566.7% | 8.34 | +0.6% | -0.2% | +2.0% | -1.3% | -1.2% | +0.6% | — |
| Aug 1, 2024 | AMC | 0.02 | 0.02 | +19.8% | 5.61 | -2.0% | -2.0% | -2.4% | +4.7% | -5.3% | +2.8% | — |
| May 2, 2024 | AMC | -0.17 | -0.03 | +82.4% | 5.17 | +4.4% | -1.4% | +1.2% | -0.8% | +0.6% | +0.4% | — |
| Apr 16, 2024 | AMC | -0.14 | -0.07 | +50.0% | 5.00 | +0.8% | -1.8% | -2.0% | +3.7% | +1.2% | +0.8% | — |
| Nov 2, 2023 | AMC | -0.17 | -0.09 | +47.1% | 7.88 | +0.5% | +4.4% | +0.7% | +0.0% | -2.8% | -6.0% | — |
| Aug 3, 2023 | AMC | -0.18 | -0.08 | +55.6% | 10.56 | +0.3% | -7.0% | -0.7% | -0.4% | -2.6% | +1.1% | — |
| May 4, 2023 | AMC | -0.22 | -0.18 | +18.2% | 11.34 | +1.6% | +1.9% | -3.2% | +0.1% | +0.4% | -2.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 3 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $15.91 | $15.61 | -1.9% | -6.3% | +2.7% | +2.0% | +0.4% | -1.0% |
| Nov 7 | Jefferies | Upgrade | Hold → Buy | — | $13.95 | $14.60 | +4.7% | +4.7% | +1.9% | +5.3% | -0.9% | -2.1% |
| Nov 5 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $14.27 | $13.78 | -3.4% | +1.3% | -3.5% | +4.7% | +1.9% | +5.3% |
| Aug 1 | RBC Capital | Maintains | Outperform → Outperform | — | $9.24 | $9.36 | +1.3% | +13.5% | +9.2% | +2.2% | -0.8% | -1.6% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.03 | $7.10 | +1.0% | +1.4% | +0.1% | -0.8% | +1.7% | +0.0% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.26 | $7.25 | -0.1% | -5.4% | -4.5% | -0.5% | +0.8% | +6.8% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.91 | $6.93 | +0.3% | +5.1% | -5.4% | -4.5% | -0.5% | +0.8% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.72 | $5.73 | +0.2% | +1.0% | -0.3% | -2.8% | -1.4% | -1.3% |
| Feb 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.00 | $5.96 | -0.7% | -0.8% | +0.8% | +0.3% | -3.0% | -2.1% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.74 | $5.70 | -0.7% | +4.5% | -0.8% | +0.8% | +0.3% | -3.0% |
| Feb 16 | RBC Capital | Maintains | Outperform → Outperform | — | $6.02 | $5.92 | -1.7% | -2.8% | -4.4% | +2.7% | +4.5% | -0.8% |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.27 | $8.34 | +0.8% | +1.0% | -2.9% | +0.7% | -2.3% | -1.3% |
| Aug 7 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $9.82 | $9.81 | -0.1% | -0.7% | -0.4% | -2.6% | +1.1% | -0.6% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jul 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.95 | $9.76 | -1.9% | +1.7% | +1.7% | +4.3% | +6.2% | -2.6% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.58 | $11.65 | +0.6% | +0.9% | -3.0% | +1.9% | -3.2% | +0.1% |
| Feb 23 | RBC Capital | Maintains | Outperform → Outperform | — | $7.91 | $8.00 | +1.1% | +6.2% | -2.5% | +1.7% | +9.1% | -1.1% |
| Jan 4 | RBC Capital | Maintains | Outperform → Outperform | — | $5.94 | $6.05 | +1.9% | +13.1% | +2.5% | +9.6% | -0.3% | +2.8% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.17 | +0.4% | -1.9% | +6.5% | -6.5% | +5.8% | -0.6% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $5.18 | $5.25 | +1.4% | -0.6% | -1.9% | +6.5% | -6.5% | +5.8% |
| Nov 4 | Oppenheimer | Downgrade | Outperform → Perform | — | $5.18 | $5.25 | +1.4% | -0.6% | -1.9% | +6.5% | -6.5% | +5.8% |
| Nov 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $5.18 | $5.25 | +1.4% | -0.6% | -1.9% | +6.5% | -6.5% | +5.8% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.27 | $8.08 | -2.3% | -1.7% | +4.6% | -3.9% | +3.1% | +2.5% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.37 | $8.30 | -0.8% | -1.2% | -1.7% | +4.6% | -3.9% | +3.1% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.37 | $11.29 | -0.7% | -4.6% | -6.4% | -12.0% | +26.0% | -15.0% |
| Apr 28 | RBC Capital | Maintains | Outperform → Outperform | — | $10.80 | $10.78 | -0.2% | -2.6% | -2.2% | +5.8% | +2.1% | +2.2% |
| Mar 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $10.67 | $10.54 | -1.2% | -5.2% | +12.5% | -5.0% | -1.8% | -5.4% |
| Mar 1 | RBC Capital | Maintains | Outperform → Outperform | — | $12.30 | $12.30 | +0.0% | -2.4% | -3.2% | -6.3% | -2.8% | +0.9% |
| Feb 23 | RBC Capital | Maintains | Outperform → Outperform | — | $15.80 | $16.17 | +2.3% | -2.9% | +4.2% | +1.6% | -24.3% | -2.4% |
| Dec 10 | Oppenheimer | Upgrade | Perform → Outperform | — | $20.97 | $21.57 | +2.9% | -4.0% | -1.1% | -9.5% | +10.3% | -1.0% |
| Nov 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $30.39 | $30.98 | +1.9% | +5.0% | +0.3% | -2.1% | -4.0% | -1.5% |
| Nov 4 | Oppenheimer | Maintains | Perform → Perform | — | $30.39 | $30.98 | +1.9% | +5.0% | +0.3% | -2.1% | -4.0% | -1.5% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.39 | $30.98 | +1.9% | +5.0% | +0.3% | -2.1% | -4.0% | -1.5% |
| Oct 28 | Oppenheimer | Downgrade | Outperform → Perform | — | $29.92 | $28.98 | -3.1% | +0.1% | +10.4% | -1.4% | -1.9% | -5.0% |
| Oct 26 | RBC Capital | Maintains | Outperform → Outperform | — | $29.84 | $29.80 | -0.1% | +1.7% | -1.4% | +0.1% | +10.4% | -1.4% |
| Jan 27 | SVB Leerink | Maintains | Outperform → Outperform | — | $17.62 | $16.77 | -4.8% | -8.9% | +6.4% | -2.2% | -2.6% | -1.3% |
| Jan 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.86 | $20.50 | +38.0% | +26.0% | -5.9% | -8.9% | +6.4% | -2.2% |
| Nov 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.50 | $13.87 | -10.5% | -9.9% | -0.9% | +2.8% | -3.3% | +0.4% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.00 | $13.76 | -1.7% | +1.3% | -0.1% | -1.1% | +3.5% | -0.6% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.48 | $15.39 | +6.3% | +15.1% | -16.3% | -0.2% | -1.0% | -2.5% |
| Mar 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $18.81 | $18.27 | -2.9% | -10.4% | -8.3% | -0.5% | -8.4% | -9.0% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.48 | $18.50 | +0.1% | +0.2% | +7.1% | -3.0% | +1.4% | +1.0% |
| Dec 16 | H.C. Wainwright | Maintains | Buy → Buy | — | $18.48 | $18.50 | +0.1% | +0.2% | +7.1% | -3.0% | +1.4% | +1.0% |
| Sep 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.80 | $6.00 | +3.4% | +12.8% | -0.5% | -0.9% | +2.2% | -2.7% |
| Mar 20 | Raymond James | Maintains | Outperform → Outperform | — | $6.42 | $6.80 | +5.9% | +6.4% | -1.2% | -4.1% | +1.9% | +0.2% |
| Feb 8 | RBC Capital | Maintains | Outperform → Outperform | — | $5.17 | $5.40 | +4.4% | -2.1% | +0.8% | +2.2% | +0.8% | +1.3% |
| Oct 23 | Leerink Swann | Maintains | Outperform → Outperform | — | $6.15 | $6.21 | +1.0% | -1.8% | -4.8% | +1.2% | -3.6% | +1.8% |
| Oct 6 | Seaport Global | Maintains | Buy → Buy | — | $6.50 | $6.61 | +1.7% | +0.9% | -2.1% | +0.2% | +0.9% | +1.4% |
| Sep 13 | Canaccord Genuity | Maintains | Buy → Speculative Buy | — | $6.38 | $6.30 | -1.3% | -2.8% | +1.9% | -0.8% | +0.0% | -1.0% |
| Apr 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.05 | $7.00 | -0.7% | -0.7% | +1.4% | -2.3% | -1.6% | -2.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | TANG KEVIN | Chief Executive Officer | Buy | 206,005 | $15.28 | $3.1M | 13,044,106 | +1.82% | +0.77% |
| Jun 1, 2026 | TANG KEVIN | Chief Executive Officer | Buy | 99 | $15.34 | $2K | 12,838,101 | +1.82% | +0.77% |
| Jun 1, 2026 | TANG KEVIN | Chief Executive Officer | Buy | 343,521 | $15.28 | $5.2M | 12,838,002 | +1.82% | +0.77% |
| May 29, 2026 | TANG KEVIN | Chief Executive Officer | Buy | 262,682 | $15.31 | $4.0M | 12,494,481 | +1.82% | +0.77% |
| May 29, 2026 | TANG KEVIN | Chief Executive Officer | Buy | 2,299 | $15.35 | $35K | 12,231,799 | +1.82% | +0.77% |
8-K
Aurinia Pharmaceuticals Inc. -- 8-K Filing
Jun 4
SC TO-T/A
! Medium
Kezar Life Sciences, Inc. -- Tender Offer Amendment
Ayala Pharmaceuticals agreed to acquire Kezar Life Sciences for $6.955 per share in cash, representing a takeover that consolidates two biotech companies.
May 11
8-K · 2.01
!!! Very High
Kezar Life Sciences, Inc. -- 8-K 2.01: Acquisition Completed
Audentes Therapeutics (AUPH) completed its acquisition of Kezar Life Sciences (KZR), combining the two biopharmaceutical companies in a deal that enhances their clinical-stage pipeline.
May 11
8-K · 2.01
!!! Very High
Aurinia Pharmaceuticals Inc. -- 8-K 2.01: Acquisition Completed
May 11
8-K · 2.02
!! High
Aurinia Pharmaceuticals Inc. -- 8-K 2.02: Earnings Results
Aurinia Pharmaceuticals reported Q1 2026 financial results, providing investors visibility into the company's operational performance and financial condition for the quarter ended March 31, 2026.
May 7
SC TO-T
!!! Very High
Unknown — Tender Offer
A tender offer for AUPH and KZR suggests potential acquisition or restructuring, making these stocks volatile short-term plays where investors should evaluate the offer price versus current trading levels and regulatory approval odds.
Apr 13
8-K
Unknown — 8-K Filing
The merger agreement requires all unvested restricted stock units to vest immediately before closing, potentially diluting shareholders and increasing acquisition costs for the acquirer.
Apr 3
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Three executives departing simultaneously signals organizational instability and increases near-term execution risk for both AUPH and KZR, likely pressuring stock prices until replacement leadership is announced.
Apr 3
8-K
Unknown — 8-K Filing
Contingent value rights (CVRs) offering shareholders potential future cash payments beyond the current offer price, which could indicate undervaluation concerns or incomplete deal certainty warranting investor caution.
Mar 30
8-K
Unknown — 8-K Filing
Aurinia's executive leadership transition with a new COO appointment signals operational restructuring; the CEO's voluntary compensation waiver suggests confidence in turnaround strategy, potentially reducing near-term cash burn.
Mar 23
8-K
Aurinia Pharmaceuticals Inc -- 8-K Filing
Aurinia Pharmaceuticals reported full-year and fourth-quarter 2025 financial results, disclosing operational performance through year-end that investors can use to assess revenue trends and cash position.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Tang Capital Management Llc | 11,329,500 | $181M | — | Dec 2025 |
| 2 | Morgan Stanley | 4,433,830 | $71M | Added | Dec 2025 |
| 3 | Two Sigma Investments, Lp | 3,428,705 | $51M | Added | Mar 2026 |
| 4 | Arrowstreet Capital, Limited Partnership | 3,284,368 | $49M | Reduced | Mar 2026 |
| 5 | Marshall Wace, Llp | 1,874,597 | $28M | Added | Mar 2026 |
| 6 | Renaissance Technologies Llc | 1,663,835 | $25M | Added | Mar 2026 |
| 7 | D.e. Shaw & Co | 1,572,983 | $23M | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 1,256,361 | $19M | New | Mar 2026 |
| 9 | Jane Street Group, Llc | 910,737 | $15M | Added | Dec 2025 |
| 10 | Nomura Holdings Inc | 968,910 | $14M | Reduced | Mar 2026 |
| 11 | Man Group Plc | 951,412 | $14M | Added | Mar 2026 |
| 12 | Aqr Capital Management Llc | 948,810 | $14M | Added | Mar 2026 |
| 13 | Qube Research & Technologies Ltd | 930,631 | $14M | Added | Mar 2026 |
| 14 | Northern Trust Corp | 824,105 | $12M | Added | Mar 2026 |
| 15 | Jupiter Asset Management Ltd | 803,419 | $12M | Reduced | Mar 2026 |
| 16 | Janus Henderson Group Plc | 757,435 | $11M | New | Mar 2026 |
| 17 | Bnp Paribas Financial Markets | 748,765 | $11M | Added | Mar 2026 |
| 18 | Nuveen, Llc | 653,424 | $10M | Reduced | Mar 2026 |
| 19 | Walleye Capital Llc | 643,134 | $10M | Added | Mar 2026 |
| 20 | Prudential Financial Inc | 590,610 | $9M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.25B
Enterprise Value
$1.94B
P/E (TTM)
7.66x
Forward P/E
21.55x
PEG Ratio
0.00x
P/B
4.05x
P/S
8.15x
P/FCF
17.96x
EV/EBITDA
12.01x
Shares Out
138.7M
Financials (TTM)
Revenue
$298.3M
Net Income
$298.2M
EBITDA
$161.8M
Free Cash Flow
$135.4M
Op Cash Flow
$135.7M
EPS Basic
$2.14
EPS Diluted
$2.16
EPS Forward
$0.81
Gross Margin
89.7%
Op Margin
41.7%
Net Margin
100.0%
Balance Sheet
Total Assets
$751.6M
Total Liab.
$170.3M
Total Equity
$581.3M
Cash
$398.0M
LT Debt
$57.2M
Book Value/Sh
$4.33
Debt/Equity
0.13x
Current Ratio
5.25
Quick Ratio
4.76
Returns & Growth
ROE
36.3%
ROA
28.1%
ROIC
15.5%
Rev Growth YoY
+20.4%
EPS Growth YoY
+5250.0%
Price Returns
2W
-3.2%
1M
-0.4%
3M
+8.2%
6M
-4.9%
12M
+95.5%
Technicals
52W High
$18.40
52W Low
$7.29
50d MA
$15.78
200d MA
$14.58
RSI (14)
68.50
ATR (14)
$0.52
Beta
1.52
Avg Volume
1.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$15.50
High
$16.00
Low
$15.00
Median
$15.50
Data updated apr 24, 2026 7:49pm
· Source: financialmodelingprep.com